Chemical and Pharmaceutical Giants Partnering with Quantum Technology Companies for Product Development
Quantum Chemicals & Quantum Life Science July 29-August 4
Large chemical and pharmaceutical enterprises are actively partnering with quantum hardware and software providers to revolutionize product development. [1, 2] Because molecular simulation and biological optimizations naturally align with quantum mechanical properties, these industries are leading early commercial adoption. [1, 2, 3, 4, 5)
Several key companies are engaging in strategic collaborations and partnerships to advance their technology and capitalize on the market’s growth according to a Fortune Business Insights Report updated in June 2026. The report cites the June 2025, collaboration between IonQ and AstraZeneca, Amazon Web Services (AWS), and NVIDIA to develop a quantum-accelerated computational chemistry workflow with the potential to drive innovation in healthcare, life sciences, chemistry, and other fields.
Corporate Partnerships with Quantum Chemicals (Materials, Performance Chemicals & Catalysts)
Chemical conglomerates are partnering with quantum technology companies to discover advanced catalysts, optimize industrial reactions, and synthesize performance materials. [1, 2]
German chemical and pharmaceutical giants like BASF and Merck KGaA are actively incorporating quantum computing by joining alliances like the Quantum Technology and Application Consortium (QUTAC) to fast-track industrial chemical simulations and materials science. [1, 2, 3]
Key Chemical Consortia Partnerships with Quantum Tech:
- QUTAC: Founded by 10 German corporate leaders—including BASF and Merck—to translate quantum computing basics into market-ready chemical applications. [1]
- SEEQC Collaboration: BASF and Merck KGaA joined as end-customer partners with SEEQC to leverage chip-based quantum platforms tailored for chemical reactions. [1]
- HQS Quantum Simulations: Partnered with firms like Merck to utilize specialized software for quantum chemistry on near-term hardware. [1]
- Boehringer Ingelheim: Partnered with Google Quantum AI to execute complex molecular simulations. They have successfully scaled up algorithmic research alongside PsiQuantum to drastically cut runtime requirements for modeling challenging, highly reactive chemical enzymes. [1, 2, 3]
- Merck KGaA: Collaborating with Oxford University and the quantum hardware startup SEEQC under a UK-led consortium. They are specifically researching the co-development of a full-stack quantum platform targeted at chemical and molecular discovery. [1)
- BMW Group: Partnered with Quantinuum to model chemical reactions inside EV batteries. They utilize quantum hardware to simulate new battery chemistries and optimize materials for superior energy density. [1, 2, 3, 4]
- Nippon Steel: Partnering with Quantinuum to research structural carbon materials and industrial catalysts. Their focus is on predicting the chemical and thermal decay properties of molecular compounds. [1]
Corporate Partnerships/Collaborations with Key Life Science and Quantum Companies for Genomics, Drug Discovery & mRNA
Pharma companies have been among the first to invest in quantum research and partnerships. Biopharma giants are forming major consortiums to simulate protein structures, optimize clinical trials, and engineer novel therapeutics. [1, 2]
Merck, Roche, Pfizer, Johnson & Johnson, and others have not only filed patents in the quantum space but also formed collaborations with quantum technology companies.
Key Life Science Collaborations with Quantum Tech
Cleveland Clinic: Formed a landmark 10-year Discovery Accelerator partnership with IBM Quantum. The collaboration focuses on CAR T-cell therapy design, structural modeling of tumor microenvironments, and running advanced quantum algorithms for clinical trial site selection. [1, 2]
Moderna: Partnering with IBM to utilize hybrid quantum-classical computing platforms. They are simulating high-dimensional mRNA secondary structures to accelerate the formulation of highly stable mRNA-based therapies. [, 2]
GlaxoSmithKline: Utilizing D-Wave Quantum hybrid solvers and IBM hardware to tackle life-science optimization problems. Their teams target peptide sequence designs and automated fragment-linking for molecular discovery. [1, 2, 3]
Amgen: Partnering with Quantinuum to execute quantum machine learning classifications for peptide binding. Additionally, they utilize IBM systems to analyze large-scale Electronic Health Records (EHR) to predict patient adherence patterns for chronic biological treatments. [, 3]
AstraZeneca: Engaged in multi-partner initiatives with IBM Quantum utilizing next-generation processors like Heron and Condor. They are evaluating machine learning methods to handle clinical data imputation and optimize lead-compound selection. [1, 2]
Biogen: Collaborating with 1QBit to utilize quantum-enhanced processing speeds for molecular structure comparison. Their research specifically focuses on accelerating discovery pipelines for complex neurological diseases like Alzheimer’s and Parkinson’s. []
QuPharma Initiative: The goal is to build application-specific quantum systems to model chemical and molecular behavior that standard supercomputers cannot handle efficiently. [1, 2]
- Focus: Improving simulation tools for complex programs like cancer photodynamic therapies. [1]
- Funding: Backed by a £6.85 million Innovate UK grant alongside consortium partners including Oxford Instruments and the University of Oxford. [1, 2]
